COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01872546
Recruitment Status : Completed
First Posted : June 7, 2013
Last Update Posted : October 11, 2016
Information provided by (Responsible Party):
Poitiers University Hospital

Brief Summary:
The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin transcriptomics profile in psoriatic patients during successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The investigators will focus on the modification of the cytokine "signature" in these skin lesions and of some markers of keratinocyte inflammation. The modification of the transcriptomics profile induced by the biotherapy will be correlated to the clinical response Psoriasis Area and Severity Index.

Condition or disease Intervention/treatment Phase
Chronic Plaque Psoriasis Drug: HUMIRA 40mg Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Actual Primary Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Adalimumab

Arm Intervention/treatment
Experimental: Adalimumab Drug: HUMIRA 40mg

Primary Outcome Measures :
  1. Analyze modifications of the skin inflammatory [ Time Frame: 1 month ]
    comparaison skin biopsy in non-lesional area between skin biopsy lesional area

Secondary Outcome Measures :
  1. skin transcriptomic profile [ Time Frame: 1 month ]
    5 mL blood sample for serum preparation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients with chronic plaque psoriasis involving at least 10% of body surface area with no previous biotherapy.
  • Adalimumab prescribed in usual practice

Exclusion Criteria:

  • Patients presenting a contraindication to the use of Adalimumab:

hypersensibility in Adalimumab or in one of the excipients.

  • Patients presenting an evolutionary tuberculosis or the other severe infections such as sepsis and opportunist infections
  • presenting patients one cardiac insufficiencies moderated in severe
  • Patients under anakinra or abatacept
  • current participation in another study of clinical research

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01872546

Layout table for location information
Chu Poitiers
Poitiers, France, 86021
Sponsors and Collaborators
Poitiers University Hospital
Layout table for additonal information
Responsible Party: Poitiers University Hospital Identifier: NCT01872546    
Other Study ID Numbers: CYTOPSO
First Posted: June 7, 2013    Key Record Dates
Last Update Posted: October 11, 2016
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases
Anti-Inflammatory Agents
Antirheumatic Agents